ClinicalTrials.gg
Active, not recruitingNCT03164616POSEIDONUpdated Mar 13, 2026Results posted

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

A Phase 3 interventional study of Durvalumab and Tremelimumab in Non Small Cell Lung Cancer NSCLC, sponsored by AstraZeneca. Active, not recruiting at 175 sites in 19 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,186
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 94
1,186 · median 74
Started
2017
with 9 others
Phase 3
17 of 94
3 open now
Primary completion
2021-03
later than 3 of 36 live
Registered
26th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 10 that started in 2017, is one of 17 in phase 3, reaches primary completion later than 3 of the 36 other live ones, and was the 26th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Read the detailed description

Adult patients with a histologically or cytologically documented metastatic NSCLC, with tumors that lack activating EGFR mutations and ALK fusions, are eligible for enrollment. Patients will be randomized in a 1:1:1 ratio to receive treatment with durvalumab + tremelimumab combination therapy + SoC chemotherapy, durvalumab monotherapy + SoC chemotherapy, or SoC chemotherapy alone. Tumor evaluation scans will be performed until objective disease progression as efficacy assessment. All patients will be followed for survival until the end of the study. An independent data monitoring committee (IDMC) composed of independent experts will be convened to confirm the safety and tolerability of the proposed dose and schedule.

03

Conditions studied

  • Non Small Cell Lung Cancer NSCLC

Keywords

  • NSCLC
  • Programmed cell death ligand 1 (PD-L1)
  • Durvalumab
  • Tremelimumab
  • Progression-free survival (PFS)
  • Overall survival (OS)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study, patients should fulfill the following criteria:

  1. Aged at least 18 years.
  2. or cytologically documented Stage IV NSCLC.
  3. Confirmed tumor status prior to randomization.
  4. Patients must have tumors that lack activating EGFR mutations and ALK fusions.
  5. No prior chemotherapy or any other systemic therapy for NSCLC.
  6. World Health Organization (WHO)/ (ECOG) performance status of 0 or 1.
  7. No prior exposure to immunemediated therapy, excluding therapeutic anticancer vaccines.

Exclusion criteria

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant.
  2. Active or prior documented or inflammatory disorders.
  3. or spinal cord compression unless the patient's condition is stable and off .
  4. Active infection including tuberculosis, , , or .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,186 participants (actual)

Study arms

  • Experimental
    Treatment Arm 1

    durvalumab + tremelimumab combination therapy + SoC chemotherapy

    Drug: Durvalumab · Drug: Tremelimumab · Drug: Abraxane + carboplatin · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + carboplatin · Drug: Pemetrexed + carboplatin · Drug: Pemetrexed + cisplatin

  • Experimental
    Treatment Arm 2

    durvalumab monotherapy + SoC chemotherapy

    Drug: Durvalumab · Drug: Abraxane + carboplatin · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + carboplatin · Drug: Pemetrexed + carboplatin · Drug: Pemetrexed + cisplatin

  • Active comparator
    Treatment Arm 3

    SoC chemotherapy alone

    Drug: Abraxane + carboplatin · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + carboplatin · Drug: Pemetrexed + carboplatin · Drug: Pemetrexed + cisplatin

Interventions

  • IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria

  • IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.

  • DrugAbraxane + carboplatin

    Drug pages: Albumin-Bound Paclitaxel · Carboplatin

    Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).

  • DrugGemcitabine + cisplatin

    Drug pages: Gemcitabine · Cisplatin

    Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).

  • DrugGemcitabine + carboplatin

    Drug pages: Gemcitabine · Carboplatin

    Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).

  • DrugPemetrexed + carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.

  • DrugPemetrexed + cisplatin

    Drug pages: Pemetrexed · Cisplatin

    Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS); D + SoC Compared With SoC Alone

    PFS (per RECIST version 1.1 \[RECIST 1.1\] using Blinded Independent Central Review \[BICR\] assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique. The final analysis of PFS in the global cohort was pre-specified after approximately 497 BICR PFS events occurred across the D + SoC and SoC alone treatment arms (75% maturity).

    Time frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).

  2. Overall Survival (OS); D + SoC Compared With SoC Alone

    OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The final analysis of OS in the global cohort was pre-specified after approximately 532 OS events occurred across the D + SoC and SoC alone treatment arms (80% maturity).

    Time frame: From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).

Secondary outcomes

  1. PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC

    PFS (per RECIST 1.1 using BICR assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months.

  2. OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC

    OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).

  3. Objective Response Rate (ORR)

    ORR (per RECIST 1.1 using BICR assessments) was defined as the percentage of patients with at least one visit response of complete response (CR) or partial response (PR). Results are presented for the pre-specified ORR analysis using unconfirmed responses based on BICR.

    Time frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).

  4. Best Objective Response (BoR)

    The BoR was calculated based on the overall visit responses from each RECIST 1.1 assessment. BOR was defined as the best response a patient had following randomization, but prior to starting any subsequent cancer therapy and up to and including RECIST 1.1 progression or the last evaluable assessment in the absence of RECIST 1.1 progression, as determined by BICR. Categorization of BoR was based on RECIST using the following 'response' categories: CR and PR and the following 'non-response' categories: stable disease (SD) ≥6 weeks, progression (ie, PD) and not evaluable (NE). Results are presented for number (%) of patients in each specified category.

    Time frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).

  5. Duration of Response (DoR)

    DoR (per RECIST 1.1 using BICR assessments) was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression. The end of response coincided with the date of progression or death from any cause used for the RECIST 1.1 PFS endpoint. The time of the initial response was defined as the latest of the dates contributing towards the first visit of PR or CR. Results are presented for the pre-specified DoR analysis using unconfirmed responses based on BICR.

    Time frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).

  6. Time From Randomization to Second Progression (PFS2)

    PFS2 was defined as the time from the date of randomization to the earliest of the progression event (subsequent to that used for the primary variable PFS) or death. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of: objective radiological imaging, symptomatic progression or death.

    Time frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).

  7. Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations

    To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of durvalumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

    Time frame: Samples were collected post-dose on Day 1 (Week 0), pre-dose on Weeks 3 and 12 and at follow-up (3 months after the last valid dose). Assessed at the global cohort DCO of 12 March 2021.

  8. PK of Tremelimumab; Peak and Trough Serum Concentrations

    To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of tremelimumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

    Time frame: Samples were collected post-dose on Day 1 (Week 0), pre-dose on Weeks 3 and 12 and at follow-up (3 months after the last valid dose). Assessed at the global cohort DCO of 12 March 2021.

  9. Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab

    Blood samples were collected at pre-specified timepoints and number of patients who developed detectable ADAs against durvalumab was determined. ADA prevalence is defined as percentage of patients with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as either treatment-induced ADA or treatment-boosted ADA. ADA incidence is percentage of patients who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted by ≥4-fold during the study period. Persistently positive is defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks (112 days) between the first and last positive, or an ADA positive result at the last available assessment. Transiently positive is defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of neutralizing antibody (nAb) was tested for all ADA positive samples.

    Time frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of study treatment (ie, durvalumab).

  10. Number of Patients With ADA Response to Tremelimumab

    Blood samples were collected at pre-specified timepoints and number of patients who developed detectable ADAs against tremelimumab was determined. ADA prevalence is defined as percentage of patients with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as either treatment-induced ADA or treatment-boosted ADA. ADA incidence is percentage of patients who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted by ≥4-fold during the study period. Persistently positive is defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks (112 days) between the first and last positive, or an ADA positive result at the last available assessment. Transiently positive is defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of nAb was tested for all ADA positive samples.

    Time frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of study treatment (ie, tremelimumab).

  11. Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)

    The EORTC QLQ-Core 30 version 3 (QLQ-C30 v3) was included for assessing HRQoL. It assesses HRQoL/health status through 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and QoL scale. 6 single-item symptom measures are also included: dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores from 0 to 100 were derived for each of the 15 domains, with higher scores representing greater functioning, greater HRQoL, or greater level of symptoms. Time to deterioration was defined as time from randomization until the date of first clinically meaningful deterioration that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever came first). Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).

  12. Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13)

    The EORTC QLQ-LC13 is a disease-specific 13-item self-administered questionnaire for lung cancer, to be used in conjunction with the EORTC QLQ-C30. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, hemoptysis, dyspnea, and pain) and treatment-related symptoms from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores from 0 to 100 were derived for each symptom item, with higher scores representing greater level of symptoms. Time to deterioration was defined as time from randomization until the date of first clinically meaningful deterioration that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever came first). Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).

07

Results

Posted Apr 7, 2022
Limitations and caveats
This study also incorporates a China tail, comprising additional patients randomized after the end of the global cohort recruitment. Efficacy and safety of patients randomized in China will be reported at a later date once this separate analysis has been completed.

Participant flow

Study was conducted in 142 study centers across 18 countries in North and Latin America, Europe, Asia Pacific and Africa. First patient randomized: 27 June 2017. Results are presented for the global cohort at final analysis data cut-offs (DCOs) of 24 July 2019 (Response Evaluation Criteria in Solid Tumors \[RECIST\]-based endpoints) and 12 March 2021 (all other data). Once global enrollment was complete, enrollment was started in mainland China. Results for the China cohort will be reported later.

Participant flow — Overall Study
MilestoneT + D + SoCD + SoCSoC Alone
Started338338337
Received treatment331335331
Completed806540
Not completed258273297
Withdrew: Death250264279
Withdrew: Lost to follow-up222
Withdrew: Withdrawal by subject6716

Outcome measures

PrimaryProgression-Free Survival (PFS); D + SoC Compared With SoC Alone

PFS (per RECIST version 1.1 \[RECIST 1.1\] using Blinded Independent Central Review \[BICR\] assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique. The final analysis of PFS in the global cohort was pre-specified after approximately 497 BICR PFS events occurred across the D + SoC and SoC alone treatment arms (75% maturity).

Time frame:
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
Reported as:
Median · months
Progression-Free Survival (PFS); D + SoC Compared With SoC Alone
monthsD + SoCSoC Alone
Progression-Free Survival (PFS); D + SoC Compared With SoC Alone5.5 (4.7 to 6.5)4.8 (4.6 to 5.8)
Statistical analysis
  • D + SoC vs SoC Alone · Log Rank · p = 0.00093 (Analysis was performed using a stratified log-rank test adjusting for PD-L1 tumor expression (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using the Breslow approach for handling ties.) · Hazard ratio (hr): 0.74 · 95% CI 0.620 to 0.885The HR and confidence interval (CI) were estimated from a stratified Cox proportional hazards model adjusting for PD-L1 (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using Efron method to control for ties.
PrimaryOverall Survival (OS); D + SoC Compared With SoC Alone

OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The final analysis of OS in the global cohort was pre-specified after approximately 532 OS events occurred across the D + SoC and SoC alone treatment arms (80% maturity).

Time frame:
From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
Reported as:
Median · months
Overall Survival (OS); D + SoC Compared With SoC Alone
monthsD + SoCSoC Alone
Overall Survival (OS); D + SoC Compared With SoC Alone13.3 (11.4 to 14.7)11.7 (10.5 to 13.1)
Statistical analysis
  • D + SoC vs SoC Alone · Log Rank · p = 0.07581 (Analysis was performed using a stratified log-rank test adjusting for PD-L1 tumor expression (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using the Breslow approach for handling ties.) · Hazard ratio (hr): 0.86 · 95% CI 0.724 to 1.016The HR and CI were estimated from a stratified Cox proportional hazards model adjusting for PD-L1 (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using Efron method to control for ties.
SecondaryPFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC

PFS (per RECIST 1.1 using BICR assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months.
Reported as:
Median · months
PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC
monthsT + D + SoCD + SoCSoC Alone
PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC6.2 (5.0 to 6.5)5.5 (4.7 to 6.5)4.8 (4.6 to 5.8)
Statistical analysis
  • T + D + SoC vs SoC Alone · Log Rank · p = 0.00031 (Analysis was performed using a stratified log-rank test adjusting for PD-L1 tumor expression (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using the Breslow approach for handling ties.) · Hazard ratio (hr): 0.72 · 95% CI 0.600 to 0.860The HR and CI were estimated from a stratified Cox proportional hazards model adjusting for PD-L1 (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using Efron method to control for ties.
SecondaryOS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC

OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
Reported as:
Median · months
OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC
monthsT + D + SoCD + SoCSoC Alone
OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC14.0 (11.7 to 16.1)13.3 (11.4 to 14.7)11.7 (10.5 to 13.1)
Statistical analysis
  • T + D + SoC vs SoC Alone · Log Rank · p = 0.00304 (Analysis was performed using a stratified log-rank test adjusting for PD-L1 tumor expression (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using the Breslow approach for handling ties.) · Hazard ratio (hr): 0.77 · 95% CI 0.650 to 0.916The HR and CI were estimated from a stratified Cox proportional hazards model adjusting for PD-L1 (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using Efron method to control for ties.
SecondaryObjective Response Rate (ORR)

ORR (per RECIST 1.1 using BICR assessments) was defined as the percentage of patients with at least one visit response of complete response (CR) or partial response (PR). Results are presented for the pre-specified ORR analysis using unconfirmed responses based on BICR.

Time frame:
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
Reported as:
Number · percentage of patients
Objective Response Rate (ORR)
percentage of patientsT + D + SoCD + SoCSoC Alone
Objective Response Rate (ORR)46.348.533.4
Statistical analysis
  • D + SoC vs SoC Alone · Odds ratio (or): 1.90 · 95% CI 1.382 to 2.619
  • T + D + SoC vs SoC Alone · Odds ratio (or): 1.72 · 95% CI 1.260 to 2.367
SecondaryBest Objective Response (BoR)

The BoR was calculated based on the overall visit responses from each RECIST 1.1 assessment. BOR was defined as the best response a patient had following randomization, but prior to starting any subsequent cancer therapy and up to and including RECIST 1.1 progression or the last evaluable assessment in the absence of RECIST 1.1 progression, as determined by BICR. Categorization of BoR was based on RECIST using the following 'response' categories: CR and PR and the following 'non-response' categories: stable disease (SD) ≥6 weeks, progression (ie, PD) and not evaluable (NE). Results are presented for number (%) of patients in each specified category.

Time frame:
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
Reported as:
Count of participants · Participants
Best Objective Response (BoR)
ParticipantsT + D + SoCD + SoCSoC Alone
CR230
PR153157111
SD ≥6 weeks120107150
PD486061
NE12310
SecondaryDuration of Response (DoR)

DoR (per RECIST 1.1 using BICR assessments) was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression. The end of response coincided with the date of progression or death from any cause used for the RECIST 1.1 PFS endpoint. The time of the initial response was defined as the latest of the dates contributing towards the first visit of PR or CR. Results are presented for the pre-specified DoR analysis using unconfirmed responses based on BICR.

Time frame:
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
Reported as:
Median · months
Duration of Response (DoR)
monthsT + D + SoCD + SoCSoC Alone
Duration of Response (DoR)7.4 (3.5 to NA)6.0 (3.4 to NA)4.2 (3.0 to 6.9)
SecondaryTime From Randomization to Second Progression (PFS2)

PFS2 was defined as the time from the date of randomization to the earliest of the progression event (subsequent to that used for the primary variable PFS) or death. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of: objective radiological imaging, symptomatic progression or death.

Time frame:
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
Reported as:
Median · months
Time From Randomization to Second Progression (PFS2)
monthsT + D + SoCD + SoCSoC Alone
Time From Randomization to Second Progression (PFS2)10.4 (9.4 to 12.2)10.2 (9.0 to 11.5)9.4 (8.6 to 10.4)
Statistical analysis
  • D + SoC vs SoC Alone · Hazard ratio (hr): 0.79 · 95% CI 0.666 to 0.928The HR and CI were estimated from a stratified Cox proportional hazards model adjusting for PD-L1 (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using Efron method to control for ties.
  • T + D + SoC vs SoC Alone · Hazard ratio (hr): 0.75 · 95% CI 0.632 to 0.883The HR and CI were estimated from a stratified Cox proportional hazards model adjusting for PD-L1 (TC ≥50% vs \<50%), histology (squamous vs non-squamous) and disease stage (IVA vs IVB) and using Efron method to control for ties.
SecondaryPharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations

To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of durvalumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

Time frame:
Samples were collected post-dose on Day 1 (Week 0), pre-dose on Weeks 3 and 12 and at follow-up (3 months after the last valid dose). Assessed at the global cohort DCO of 12 March 2021.
Reported as:
Geometric mean · micrograms/milliliter (μg/mL)
Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations
micrograms/milliliter (μg/mL)T + D + SoCD + SoC
Week 0418.80 ± 164.20505.01 ± 48.76
Week 382.08 ± 84.3891.53 ± 100.58
Week 12195.62 ± 58.65212.11 ± 60.37
Follow-up (3 months)13.42 ± 166.3616.06 ± 249.88
SecondaryPK of Tremelimumab; Peak and Trough Serum Concentrations

To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of tremelimumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

Time frame:
Samples were collected post-dose on Day 1 (Week 0), pre-dose on Weeks 3 and 12 and at follow-up (3 months after the last valid dose). Assessed at the global cohort DCO of 12 March 2021.
Reported as:
Geometric mean · μg/mL
PK of Tremelimumab; Peak and Trough Serum Concentrations
μg/mLT + D + SoC
Week 023.17 ± 65.62
Week 34.16 ± 80.83
Week 127.82 ± 75.68
Follow-up (3 months)0.86 ± 87.65
SecondaryNumber of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab

Blood samples were collected at pre-specified timepoints and number of patients who developed detectable ADAs against durvalumab was determined. ADA prevalence is defined as percentage of patients with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as either treatment-induced ADA or treatment-boosted ADA. ADA incidence is percentage of patients who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted by ≥4-fold during the study period. Persistently positive is defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks (112 days) between the first and last positive, or an ADA positive result at the last available assessment. Transiently positive is defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of neutralizing antibody (nAb) was tested for all ADA positive samples.

Time frame:
Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of study treatment (ie, durvalumab).
Reported as:
Count of participants · Participants
Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab
ParticipantsT + D + SoCD + SoC
ADA positive at any visit (ADA prevalence)4233
Treatment-emergent ADA positive (ADA incidence)2919
Treatment-boosted ADA21
Treatment-induced ADA (ADA positive post-baseline only)2718
ADA positive at baseline only813
ADA positive post-baseline and positive at baseline72
Persistently positive87
Transiently positive2613
nAb positive at any visit33
SecondaryNumber of Patients With ADA Response to Tremelimumab

Blood samples were collected at pre-specified timepoints and number of patients who developed detectable ADAs against tremelimumab was determined. ADA prevalence is defined as percentage of patients with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as either treatment-induced ADA or treatment-boosted ADA. ADA incidence is percentage of patients who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted by ≥4-fold during the study period. Persistently positive is defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks (112 days) between the first and last positive, or an ADA positive result at the last available assessment. Transiently positive is defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of nAb was tested for all ADA positive samples.

Time frame:
Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of study treatment (ie, tremelimumab).
Reported as:
Count of participants · Participants
Number of Patients With ADA Response to Tremelimumab
ParticipantsT + D + SoC
ADA positive at any visit (ADA prevalence)44
Treatment-emergent ADA positive (ADA incidence)38
Treatment-boosted ADA3
Treatment-induced ADA (ADA positive post-baseline only)35
ADA positive at baseline only4
ADA positive post-baseline and positive at baseline5
Persistently positive22
Transiently positive18
nAb positive at any visit31
SecondaryTime to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)

The EORTC QLQ-Core 30 version 3 (QLQ-C30 v3) was included for assessing HRQoL. It assesses HRQoL/health status through 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and QoL scale. 6 single-item symptom measures are also included: dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores from 0 to 100 were derived for each of the 15 domains, with higher scores representing greater functioning, greater HRQoL, or greater level of symptoms. Time to deterioration was defined as time from randomization until the date of first clinically meaningful deterioration that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever came first). Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
Reported as:
Median · months
Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)
monthsT + D + SoCD + SoCSoC Alone
QLQ-C30 Global Health Status / HRQoL8.3 (6.4 to 10.2)7.8 (6.5 to 9.5)5.6 (4.4 to 7.5)
QLQ-C30 Physical Functioning7.7 (5.9 to 9.4)8.3 (6.6 to 10.0)5.3 (4.2 to 6.5)
QLQ-C30 Role Functioning6.6 (5.4 to 8.3)7.4 (5.8 to 9.3)4.8 (3.6 to 6.2)
QLQ-C30 Cognitive Functioning7.6 (6.1 to 9.7)7.4 (5.6 to 9.3)5.8 (4.6 to 7.5)
QLQ-C30 Emotional Functioning8.5 (6.6 to 11.3)9.5 (7.4 to 12.0)7.5 (5.8 to 11.0)
QLQ-C30 Social Functioning6.4 (5.6 to 9.4)7.1 (5.0 to 9.6)5.7 (4.6 to 7.4)
QLQ-C30 Fatigue3.7 (2.8 to 5.0)3.8 (2.9 to 4.9)2.8 (2.1 to 3.7)
QLQ-C30 Pain8.9 (6.2 to 10.9)6.5 (5.6 to 8.6)5.7 (4.6 to 7.2)
QLQ-C30 Nausea / Vomiting7.8 (5.6 to 10.0)5.6 (4.1 to 6.6)5.6 (4.2 to 7.5)
QLQ-C30 Dyspnea7.9 (5.8 to 9.8)6.9 (5.8 to 8.9)6.7 (5.5 to 8.8)
QLQ-C30 Insomnia8.3 (6.4 to 10.4)7.4 (5.6 to 9.8)5.8 (4.2 to 7.2)
QLQ-C30 Appetite Loss7.2 (5.7 to 9.4)7.2 (4.7 to 8.8)7.0 (5.6 to 9.6)
QLQ-C30 Constipation9.2 (6.4 to 12.2)8.7 (6.5 to 10.0)6.1 (4.8 to 7.5)
QLQ-C30 Diarrhea11.0 (9.3 to 13.6)9.8 (8.1 to 12.9)10.8 (9.2 to 15.1)
SecondaryTime to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13)

The EORTC QLQ-LC13 is a disease-specific 13-item self-administered questionnaire for lung cancer, to be used in conjunction with the EORTC QLQ-C30. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, hemoptysis, dyspnea, and pain) and treatment-related symptoms from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores from 0 to 100 were derived for each symptom item, with higher scores representing greater level of symptoms. Time to deterioration was defined as time from randomization until the date of first clinically meaningful deterioration that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever came first). Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
Reported as:
Median · months
Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13)
monthsT + D + SoCD + SoCSoC Alone
QLQ-LC13 Cough9.7 (7.3 to 13.3)11.0 (8.7 to 13.5)8.8 (6.8 to 12.3)
QLQ-LC13 Hemoptysis17.8 (12.5 to 31.3)14.0 (10.3 to 21.4)11.4 (9.3 to 19.3)
QLQ-LC13 Dyspnea5.4 (4.2 to 6.4)5.0 (3.8 to 6.4)3.6 (2.6 to 4.5)
QLQ-LC13 Pain in Chest10.0 (7.7 to 13.3)9.5 (7.8 to 11.8)8.6 (6.8 to 11.4)
QLQ-LC13 Pain in Arm or Shoulder8.9 (6.6 to 10.9)8.9 (7.4 to 10.3)8.8 (6.2 to 12.0)
QLQ-LC13 Pain in Other Parts9.7 (6.8 to 12.1)8.9 (6.8 to 11.2)5.8 (4.9 to 9.3)

Adverse events

Collected over Adverse events: from first dose of study treatment until the earlier of 90 days after last dose or the date of first subsequent anticancer therapy. All-cause mortality (death due to any cause): from randomization up to global cohort final analysis DCO (12 March 2021). Maximum timeframe of approximately 45 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T + D + SoC251/338 (74.3%)146/330 (44.2%)309/330 (93.6%)
D + SoC265/338 (78.4%)134/334 (40.1%)302/334 (90.4%)
SoC Alone285/337 (84.6%)117/333 (35.1%)301/333 (90.4%)
Most frequent serious events
Showing 10 of 246
Most frequent serious events
EventT + D + SoCD + SoCSoC Alone
PneumoniaInfections and infestations36/33021/33416/333
AnaemiaBlood and lymphatic system disorders18/33023/33421/333
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/3304/3349/333
DiarrhoeaGastrointestinal disorders8/3303/3342/333
PyrexiaGeneral disorders8/3301/3341/333
ThrombocytopeniaBlood and lymphatic system disorders8/3306/3343/333
Febrile neutropeniaBlood and lymphatic system disorders7/3305/3344/333
HaemoptysisRespiratory, thoracic and mediastinal disorders2/3307/3343/333
Acute kidney injuryRenal and urinary disorders6/3304/3341/333
PneumonitisRespiratory, thoracic and mediastinal disorders6/3305/3341/333
Most frequent other events
Showing 10 of 47
Most frequent other events
EventT + D + SoCD + SoCSoC Alone
AnaemiaBlood and lymphatic system disorders150/330137/334146/333
NauseaGastrointestinal disorders136/330120/334121/333
NeutropeniaBlood and lymphatic system disorders98/33075/33477/333
Decreased appetiteMetabolism and nutrition disorders92/33071/33481/333
FatigueGeneral disorders81/33080/33474/333
ConstipationGastrointestinal disorders63/33072/33479/333
DiarrhoeaGastrointestinal disorders65/33057/33449/333
RashSkin and subcutaneous tissue disorders63/33046/33422/333
VomitingGastrointestinal disorders59/33051/33445/333
Neutrophil count decreasedInvestigations39/33046/33459/333

Baseline characteristics

Global cohort: All patients in the full analysis set (FAS), which included all randomized patients, were included in the baseline analysis. Patients were included in the analysis in the treatment arm to which they were randomized, regardless of the treatment they received.

Age, Continuous
Age, Continuous(years)T + D + SoCD + SoCSoC AloneTotal
Mean62.6 ± 9.4363.5 ± 9.1063.1 ± 9.8763.1 ± 9.47
Sex: Female, Male
Sex: Female, Male(Participants)T + D + SoCD + SoCSoC AloneTotal
Female698589243
Male269253248770
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)T + D + SoCD + SoCSoC AloneTotal
White205182179566
Black or African American84820
Asian99123128350
Native Hawaiian or other Pacific Islander2002
American Indian or Alaska Native1217938
Other12121337
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)T + D + SoCD + SoCSoC AloneTotal
Hispanic or Latino515455160
Not Hispanic or Latino287284282853
Age Categorical
Age Categorical(Participants)T + D + SoCD + SoCSoC AloneTotal
≥18 to <5029273086
≥50 to <65162142146450
≥65 to <75112130121363
≥75353940114
08

Study locations

175 sites
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Kansas City, Missouri 64132, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30380-472, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Ribeirão Preto, 14015-140, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Santo André, 09060-650, Brazil
  • Research Site
    Santo André, 09080-110, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01209-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changchun, 130012, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Kunming, CN-650034, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Liuzhou, 545006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Qingdao, 110016, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shantou, 515041, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xining, 810001, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhanjiang, 524001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Essen, 45122, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Hamburg, 20251, Germany
  • Research Site
    Hamburg, 21075, Germany
  • Research Site
    Heidelberg, 69126, Germany
  • Research Site
    Immenhausen, 34376, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Oldenburg, 26121, Germany
  • Research Site
    Würzburg, 97067, Germany
  • Research Site
    Shatin, 00000, Hong Kong
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Bunkyō City, 113-8603, Japan
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Hiroshima, 730-0011, Japan
  • Research Site
    Iwakuni-shi, 740-8510, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Matsuyama, 790-0007, Japan
  • Research Site
    Okayama, 700-8558, Japan
  • Research Site
    Okayama, 700-8607, Japan
  • Research Site
    Sapporo, 003-0804, Japan
  • Research Site
    Sayama, 589-8511, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Toyoake-shi, 470-1101, Japan
  • Research Site
    Ube-shi, 755-0241, Japan
  • Research Site
    Yokohama, 236-0004, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Cuautitlán Izcalli, 54769, Mexico

Showing the first 100 of 175 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial. J Thorac Oncol. 2025 Jan;20(1):76-93. doi: 10.1016/j.jtho.2024.09.1381. Epub 2024 Sep 5. PubMed 39243945 ↗
  • He JZ, Duval V, Jauslin P, Goncalves A, Abegesah A, Fan C, Lim K, Song X, Chen C, Shi X, Mann H, Krug L, Ren S, Phipps A, Gibbs M, Zhou D. Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study. Clin Pharmacol Ther. 2023 Dec;114(6):1375-1386. doi: 10.1002/cpt.3063. Epub 2023 Oct 17. PubMed 37777827 ↗
  • Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3. PubMed 36327426 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Mar 2021, 45 months.

Results were first posted in Apr 2022, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 45 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2017
First posted
May 23, 2017
StartActual
Jun 1, 2017
Primary completionActual
Mar 12, 2021
CompletionEst.
Nov 15, 2027
Results first posted
Apr 7, 2022
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03164616
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 23, 2017
Start date
Jun 1, 2017
Primary completion
Mar 12, 2021
Completion
Nov 15, 2027 (estimated)
Results posted
Apr 7, 2022
Last update
Mar 13, 2026

Study contacts

Xiaojin Shi, M.D., MSc
study director · One MedImmune Way, Gaithersburg, Maryland 20878, United States

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion